WO2009156092A3 - Bi-and polycyclic substituted isoquinoline and isoquinoline derivatives as rho kinase inhibitors - Google Patents

Bi-and polycyclic substituted isoquinoline and isoquinoline derivatives as rho kinase inhibitors Download PDF

Info

Publication number
WO2009156092A3
WO2009156092A3 PCT/EP2009/004393 EP2009004393W WO2009156092A3 WO 2009156092 A3 WO2009156092 A3 WO 2009156092A3 EP 2009004393 W EP2009004393 W EP 2009004393W WO 2009156092 A3 WO2009156092 A3 WO 2009156092A3
Authority
WO
WIPO (PCT)
Prior art keywords
isoquinoline
kinase inhibitors
polycyclic substituted
rho kinase
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/004393
Other languages
French (fr)
Other versions
WO2009156092A2 (en
Inventor
Oliver Plettenburg
Katrin Lorenz
Matthias Loehn
Olivier Duclos
Sandrine Biscarrat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PL09768941T priority Critical patent/PL2303845T3/en
Priority to EP09768941.8A priority patent/EP2303845B1/en
Priority to CN200980124285.7A priority patent/CN102076667B/en
Priority to US13/000,202 priority patent/US8524737B2/en
Priority to NZ590067A priority patent/NZ590067A/en
Priority to ES09768941T priority patent/ES2434121T3/en
Priority to MX2010013867A priority patent/MX2010013867A/en
Priority to KR1020107028889A priority patent/KR101692211B1/en
Priority to BRPI0914330A priority patent/BRPI0914330A2/en
Priority to JP2011515170A priority patent/JP5715561B2/en
Priority to SI200930775T priority patent/SI2303845T1/en
Priority to RU2011102460/04A priority patent/RU2532481C2/en
Priority to AU2009262509A priority patent/AU2009262509B2/en
Priority to HRP20131040AT priority patent/HRP20131040T1/en
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to DK09768941.8T priority patent/DK2303845T3/en
Priority to HK11106455.2A priority patent/HK1152308B/en
Priority to CA2728123A priority patent/CA2728123C/en
Publication of WO2009156092A2 publication Critical patent/WO2009156092A2/en
Publication of WO2009156092A3 publication Critical patent/WO2009156092A3/en
Priority to ZA2010/08120A priority patent/ZA201008120B/en
Priority to MA33439A priority patent/MA32401B1/en
Priority to IL210114A priority patent/IL210114A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)

Abstract

The invention relates to bi- and polycyclic substituted isoquinoline and isoquinolinones of the formula (I) wherein R1 to R12 are as defined in the application useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.
PCT/EP2009/004393 2008-06-24 2009-06-18 Bi- and polycyclic substituted isoquinoline and isoquinolinone derivatives Ceased WO2009156092A2 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
AU2009262509A AU2009262509B2 (en) 2008-06-24 2009-06-18 Bi-and polycyclic substituted isoquinoline and isoquinoline derivatives as Rho kinase inhibitors
CN200980124285.7A CN102076667B (en) 2008-06-24 2009-06-18 Bicyclic and polycyclic substituted isoquinoline and isoquinolinone derivatives
US13/000,202 US8524737B2 (en) 2008-06-24 2009-06-18 Bi- and polycyclic substituted isoquinoline and isoquinolinone derivatives
NZ590067A NZ590067A (en) 2008-06-24 2009-06-18 Bi-and polycyclic substituted isoquinoline and isoquinolinone derivatives as rho kinase inhibitors
ES09768941T ES2434121T3 (en) 2008-06-24 2009-06-18 Isoquinoline and isoquinolinone bi- and substituted polycyclic derivatives as rho kinase inhibitors
MX2010013867A MX2010013867A (en) 2008-06-24 2009-06-18 Bi-and polycyclic substituted isoquinoline and isoquinoline derivatives as rho kinase inhibitors.
KR1020107028889A KR101692211B1 (en) 2008-06-24 2009-06-18 Bi- and polycyclic substituted isoquinoline and isoquinolinone derivatives as Rho kinase inhibitors
BRPI0914330A BRPI0914330A2 (en) 2008-06-24 2009-06-18 polycyclic substituted isoquinoline and isoquinolinone derivatives
EP09768941.8A EP2303845B1 (en) 2008-06-24 2009-06-18 Bi-and polycyclic substituted isoquinoline and isoquinoline derivatives as rho kinase inhibitors
SI200930775T SI2303845T1 (en) 2008-06-24 2009-06-18 Bi-and polycyclic substituted isoquinoline and isoquinoline derivatives as rho kinase inhibitors
RU2011102460/04A RU2532481C2 (en) 2008-06-24 2009-06-18 Bi- and polycyclic substituted isoquinoline and isoquinolinone derivatives, useful as rho-kinase inhibitors
PL09768941T PL2303845T3 (en) 2008-06-24 2009-06-18 Bi-and polycyclic substituted isoquinoline and isoquinoline derivatives as rho kinase inhibitors
JP2011515170A JP5715561B2 (en) 2008-06-24 2009-06-18 Bi- and polycyclic substituted isoquinoline and isoquinolinone derivatives
HRP20131040AT HRP20131040T1 (en) 2008-06-24 2009-06-18 BI- AND POLYCYCLIC SUBSTITUTED ISOQINOLINE AND ISOQINOLINE DERIVATIVES AS RHO-KINASE INHIBITORS
DK09768941.8T DK2303845T3 (en) 2008-06-24 2009-06-18 Bi and polycyclic substituted isoquinoline and bi and polycyclic substituted isoquinoline derivatives as rho kinase inhibitors
HK11106455.2A HK1152308B (en) 2008-06-24 2009-06-18 Bi- and polycyclic substituted isoquinoline and isoquinolinone derivatives
CA2728123A CA2728123C (en) 2008-06-24 2009-06-18 Bi- and polycyclic substituted isoquinoline and isoquinolinone derivatives
ZA2010/08120A ZA201008120B (en) 2008-06-24 2010-11-12 Bi-and polycyclic substituted isoquinoline and isoquinoline derivatives as rho kinase inhibitors
MA33439A MA32401B1 (en) 2008-06-24 2010-12-17 ISOQUINOLINE AND ISOQUINOLEINONE DERIVATIVES SUBSTITUTED BI-AND POLYCYCLIC
IL210114A IL210114A (en) 2008-06-24 2010-12-20 Bi-and polycyclic substituted isoquinoline and isoquinolinone derivatives

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP08290607.4 2008-06-24
EP08290607 2008-06-24
US15315509P 2009-02-17 2009-02-17
US61/153,155 2009-02-17

Publications (2)

Publication Number Publication Date
WO2009156092A2 WO2009156092A2 (en) 2009-12-30
WO2009156092A3 true WO2009156092A3 (en) 2010-04-08

Family

ID=40076742

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/004393 Ceased WO2009156092A2 (en) 2008-06-24 2009-06-18 Bi- and polycyclic substituted isoquinoline and isoquinolinone derivatives

Country Status (26)

Country Link
US (1) US8524737B2 (en)
EP (1) EP2303845B1 (en)
JP (1) JP5715561B2 (en)
KR (1) KR101692211B1 (en)
CN (1) CN102076667B (en)
AR (1) AR072279A1 (en)
AU (1) AU2009262509B2 (en)
BR (1) BRPI0914330A2 (en)
CA (1) CA2728123C (en)
CO (1) CO6321251A2 (en)
DK (1) DK2303845T3 (en)
ES (1) ES2434121T3 (en)
HR (1) HRP20131040T1 (en)
IL (1) IL210114A (en)
MA (1) MA32401B1 (en)
MX (1) MX2010013867A (en)
MY (1) MY153756A (en)
NZ (1) NZ590067A (en)
PL (1) PL2303845T3 (en)
PT (1) PT2303845E (en)
RU (1) RU2532481C2 (en)
SI (1) SI2303845T1 (en)
TW (1) TWI466868B (en)
UY (1) UY31924A (en)
WO (1) WO2009156092A2 (en)
ZA (1) ZA201008120B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3017868A1 (en) 2014-02-21 2015-08-28 Servier Lab ISOQUINOLINE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007012422A1 (en) * 2005-07-26 2007-02-01 Sanofi-Aventis Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors
WO2007039563A1 (en) * 2005-09-30 2007-04-12 N.V. Organon 9-azabicyclo [3 . 3 . 1] nonane derivatives as monoamine reuptake inhibitors
WO2008077556A1 (en) * 2006-12-27 2008-07-03 Sanofi-Aventis Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives
WO2008077555A2 (en) * 2006-12-27 2008-07-03 Sanofi-Aventis Substituted isoquinolines and their use as rho-kinase inhibitors

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2702600A1 (en) * 1977-01-22 1978-07-27 Thomae Gmbh Dr K NEW AMINOALCOXYPHENYL DERIVATIVES
FR2485537B2 (en) 1977-04-13 1986-05-16 Anvar DIPYRIDO (4,3-B) (3,4-F) INDOLES, PROCESS FOR OBTAINING IT, THERAPEUTIC APPLICATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JPH06501921A (en) 1990-07-31 1994-03-03 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー Catalytic equilibration of selected halocarbons
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9516709D0 (en) 1995-08-15 1995-10-18 Zeneca Ltd Medicament
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
NZ513800A (en) 1996-08-12 2001-09-28 Welfide Corp Treatment of diseases using Rho kinase inhibitors
JPH1087629A (en) 1996-09-18 1998-04-07 Fujisawa Pharmaceut Co Ltd New isoquinoline derivative, and its medicinal use
JP2001514259A (en) 1997-08-29 2001-09-11 ゼネカ・リミテッド Aminomethyloxooxazolidinylbenzene derivatives
TW575567B (en) * 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
GB9912701D0 (en) 1999-06-01 1999-08-04 Smithkline Beecham Plc Novel compounds
US6541456B1 (en) 1999-12-01 2003-04-01 Isis Pharmaceuticals, Inc. Antimicrobial 2-deoxystreptamine compounds
IL150650A0 (en) 2000-01-20 2003-02-12 Eisai Co Ltd Piperidine derivatives and pharmaceutical compositions containing the same
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
WO2001064238A2 (en) 2000-02-29 2001-09-07 Curis, Inc. Methods and compositions for regulating adipocytes
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AR033517A1 (en) 2000-04-08 2003-12-26 Astrazeneca Ab PIPERIDINE DERIVATIVES, PROCESS FOR THE PREPARATION AND USE OF THESE DERIVATIVES IN THE MANUFACTURE OF MEDICINES
GB0013060D0 (en) 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
WO2002034712A1 (en) 2000-10-27 2002-05-02 Takeda Chemical Industries, Ltd. Process for preparing substituted aromatic compounds and intermediates therefor
WO2002055496A1 (en) 2001-01-15 2002-07-18 Glaxo Group Limited Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
SE0101038D0 (en) 2001-03-23 2001-03-23 Astrazeneca Ab Novel compounds
WO2002088101A2 (en) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Inhibitors of bace
JPWO2002100833A1 (en) 2001-06-12 2004-09-24 住友製薬株式会社 Rho kinase inhibitor
GB0117899D0 (en) 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
WO2003024450A1 (en) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating prion diseases
SE0104340D0 (en) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
AU2003281623B8 (en) * 2002-07-22 2009-06-11 Asahi Kasei Pharma Corporation 5-substituted isoquinoline derivative
EP1550660A1 (en) 2002-09-12 2005-07-06 Kirin Beer Kabushiki Kaisha Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same
WO2004105757A2 (en) 2003-05-29 2004-12-09 Schering Aktiengesellschaft Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
EP1638939A2 (en) 2003-06-24 2006-03-29 Neurosearch A/S Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
JP4794446B2 (en) 2003-09-23 2011-10-19 メルク・シャープ・エンド・ドーム・コーポレイション Isoquinoline potassium channel inhibitor
WO2005030791A2 (en) 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
US20050067037A1 (en) 2003-09-30 2005-03-31 Conocophillips Company Collapse resistant composite riser
JPWO2005035516A1 (en) 2003-10-10 2006-12-21 小野薬品工業株式会社 Novel fused heterocyclic compounds and uses thereof
WO2005054202A1 (en) 2003-11-25 2005-06-16 Eli Lilly And Company 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b)
WO2005074535A2 (en) 2004-01-30 2005-08-18 Eisai Co., Ltd. Cholinesterase inhibitors for spinal cord disorders
EP1729761A4 (en) 2004-03-05 2008-09-03 Eisai Co Ltd Cadasil treatment with cholinesterase inhibitors
SE0400850D0 (en) 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
NZ565040A (en) 2005-06-28 2010-05-28 Sanofi Aventis Isoquinoline derivatives as inhibitors of RHO-kinase
KR101373535B1 (en) 2005-07-26 2014-03-12 사노피 Piperidinyl-substituted isoquinolone derivatives as Rho-kinase inhibitors
TW200738682A (en) 2005-12-08 2007-10-16 Organon Nv Isoquinoline derivatives
US7618985B2 (en) 2005-12-08 2009-11-17 N.V. Organon Isoquinoline derivatives
US7893088B2 (en) 2006-08-18 2011-02-22 N.V. Organon 6-substituted isoquinoline derivatives
WO2008036540A2 (en) * 2006-09-20 2008-03-27 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
KR20090103903A (en) 2006-12-27 2009-10-01 사노피-아벤티스 Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives
EP2114920A1 (en) 2006-12-27 2009-11-11 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives
KR20090092303A (en) 2006-12-27 2009-08-31 사노피-아벤티스 Cycloalkylamine substituted isoquinoline derivatives
RU2455302C2 (en) 2006-12-27 2012-07-10 Санофи-Авентис SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES AS Rho-KINASE INHIBITORS
NZ577980A (en) 2006-12-27 2012-01-12 Sanofi Aventis Cycloalkylamine substituted isoquinolone derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007012422A1 (en) * 2005-07-26 2007-02-01 Sanofi-Aventis Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors
WO2007039563A1 (en) * 2005-09-30 2007-04-12 N.V. Organon 9-azabicyclo [3 . 3 . 1] nonane derivatives as monoamine reuptake inhibitors
WO2008077556A1 (en) * 2006-12-27 2008-07-03 Sanofi-Aventis Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives
WO2008077555A2 (en) * 2006-12-27 2008-07-03 Sanofi-Aventis Substituted isoquinolines and their use as rho-kinase inhibitors

Also Published As

Publication number Publication date
NZ590067A (en) 2012-09-28
ES2434121T3 (en) 2013-12-13
TW201014825A (en) 2010-04-16
JP2011525508A (en) 2011-09-22
MA32401B1 (en) 2011-06-01
HRP20131040T1 (en) 2013-12-06
US20110190340A1 (en) 2011-08-04
CA2728123C (en) 2017-02-21
EP2303845B1 (en) 2013-09-18
MY153756A (en) 2015-03-13
PT2303845E (en) 2013-11-25
CO6321251A2 (en) 2011-09-20
IL210114A0 (en) 2011-02-28
PL2303845T3 (en) 2014-03-31
EP2303845A2 (en) 2011-04-06
WO2009156092A2 (en) 2009-12-30
JP5715561B2 (en) 2015-05-07
SI2303845T1 (en) 2013-12-31
CN102076667B (en) 2014-03-26
TWI466868B (en) 2015-01-01
IL210114A (en) 2014-07-31
KR101692211B1 (en) 2017-01-03
BRPI0914330A2 (en) 2019-09-24
KR20110026430A (en) 2011-03-15
RU2532481C2 (en) 2014-11-10
AU2009262509B2 (en) 2014-01-30
AR072279A1 (en) 2010-08-18
AU2009262509A1 (en) 2009-12-30
DK2303845T3 (en) 2013-12-16
UY31924A (en) 2010-01-29
MX2010013867A (en) 2011-02-24
CN102076667A (en) 2011-05-25
ZA201008120B (en) 2011-08-31
US8524737B2 (en) 2013-09-03
RU2011102460A (en) 2012-07-27
CA2728123A1 (en) 2009-12-30
HK1152308A1 (en) 2012-02-24

Similar Documents

Publication Publication Date Title
WO2008077555A3 (en) Substituted isoquinolines and their use as rho-kinase inhibitors
TNSN08039A1 (en) Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors
MY157330A (en) Substituted isoquinolinones as rho kinase inhibitors
MY146037A (en) Isoquinoline derivatives as inhibitors of rho-kinase
TN2009000270A1 (en) Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase
TNSN08038A1 (en) Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors
SV2009003317A (en) ISOQUINOLIN AND ISOQUINOLINONA DERIVATIVES REPLACED IN QUALITY OF RHO-QUINASA INHIBITORS
TN2009000268A1 (en) Substituted isoquinoline and isoquinolinone derivatives
TN2009000269A1 (en) Cycloalkylamine substituted isoquinolone derivatives
MY154767A (en) Cycloalkyamine substituted isoquinoline and isoquinolinone derivatives
DK2125744T3 (en) Cycloalkylamine-substituted isoquinolone and isoquinolinone derivatives
WO2009156092A3 (en) Bi-and polycyclic substituted isoquinoline and isoquinoline derivatives as rho kinase inhibitors
WO2009156099A8 (en) 6-substituted isoquinolines and isoquinolinones
TN2010000589A1 (en) Substituted dsoquinolines and isoquinodlinones as rho kinase inhibitors
NO20080419L (en) Isoquinoline derivatives as inhibitors of Rho kinase

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980124285.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09768941

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12010502818

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2728123

Country of ref document: CA

Ref document number: MX/A/2010/013867

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2010001489

Country of ref document: CL

Ref document number: 210114

Country of ref document: IL

Ref document number: 590067

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2009262509

Country of ref document: AU

Ref document number: 10160337

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2011515170

Country of ref document: JP

Kind code of ref document: A

Ref document number: 20107028889

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: DZP2010000787

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 8428/CHENP/2010

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009768941

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009262509

Country of ref document: AU

Date of ref document: 20090618

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011102460

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 13000202

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0914330

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20101222